JP2012524278A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524278A5
JP2012524278A5 JP2012506186A JP2012506186A JP2012524278A5 JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5 JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5
Authority
JP
Japan
Prior art keywords
cancer
histone
h3k18ac
low
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524278A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031112 external-priority patent/WO2010120942A2/en
Publication of JP2012524278A publication Critical patent/JP2012524278A/ja
Publication of JP2012524278A5 publication Critical patent/JP2012524278A5/ja
Pending legal-status Critical Current

Links

JP2012506186A 2009-04-14 2010-04-14 がんの臨床診断および予後診断のためのヒストン修飾パターン Pending JP2012524278A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16921609P 2009-04-14 2009-04-14
US16921209P 2009-04-14 2009-04-14
US61/169,212 2009-04-14
US61/169,216 2009-04-14
US22516209P 2009-07-13 2009-07-13
US61/225,162 2009-07-13
PCT/US2010/031112 WO2010120942A2 (en) 2009-04-14 2010-04-14 Histone modification patterns for clinical diagnosis and prognosis of cancer

Publications (2)

Publication Number Publication Date
JP2012524278A JP2012524278A (ja) 2012-10-11
JP2012524278A5 true JP2012524278A5 (https=) 2013-06-13

Family

ID=42983132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506186A Pending JP2012524278A (ja) 2009-04-14 2010-04-14 がんの臨床診断および予後診断のためのヒストン修飾パターン

Country Status (8)

Country Link
US (1) US20120094949A1 (https=)
EP (1) EP2419737A4 (https=)
JP (1) JP2012524278A (https=)
CN (1) CN102460173A (https=)
AU (1) AU2010236415A1 (https=)
BR (1) BRPI1013546A2 (https=)
CA (1) CA2758933A1 (https=)
WO (1) WO2010120942A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
PT2788767T (pt) * 2011-12-07 2017-12-06 Belgian Volition Sprl Método de detecção de adutos de nucleosoma
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
SG11201605259QA (en) * 2013-12-30 2016-07-28 Agency Science Tech & Res Methods for measuring biomarkers in gastrointestinal cancer
JP2016044993A (ja) * 2014-08-20 2016-04-04 有限会社マイテック ヒストン化学修飾判定による癌診断方法
CN107209190B (zh) * 2014-10-29 2021-07-16 比利时意志有限责任公司 用于富集循环肿瘤dna的方法
US10639349B2 (en) 2015-04-06 2020-05-05 The Johns Hopkins University H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11015226B2 (en) * 2015-10-06 2021-05-25 Ontario Institute For Cancer Research (Oicr) Targeting the histone pathway to detect and overcome anthracyclin resistance
GB201612815D0 (en) * 2016-07-25 2016-09-07 Belgian Volition Sa Novel combination test
EP3497451B1 (en) * 2016-08-09 2025-06-18 B.R.A.H.M.S GmbH Histones and/or proadm as markers indicating an adverse event
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110221072B (zh) * 2019-06-10 2022-08-02 东南大学 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用
CN112904006B (zh) * 2021-01-28 2022-12-27 中山大学 一种乳腺癌预后预测分子标志物及其应用
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途
WO2024233383A1 (en) * 2023-05-05 2024-11-14 University Of Utah Research Foundation Systems and methods for point-of-care assessment based on pathology image analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
WO2006119264A2 (en) * 2005-04-29 2006-11-09 The Regents Of The University Of California Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
WO2007015947A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies

Similar Documents

Publication Publication Date Title
JP2012524278A5 (https=)
Zhou et al. Increased expression of long-noncoding RNA ZFAS1 is associated with epithelial-mesenchymal transition of gastric cancer
Khan et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer
Lohaus et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Maráz et al. Thrombocytosis has a negative prognostic value in lung cancer
Chen et al. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
Carr et al. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro
e Silva et al. Assessment of kidney function in patients with cancer
Zhao et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma
Zhang et al. The prognostic value of the preoperative albumin to alkaline phosphatase ratio in patients with non‐small cell lung cancer after surgery
Dabner et al. Merkel cell Polyomavirus and p63 status in Merkel cell carcinoma by immunohistocnemistry: Merkel cell Polyomavirus positivity is inversely correlated with sun damage, but neither is correlated with outcome
Ge et al. Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma
Fiala et al. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib
Dirican et al. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha
Martí et al. Prognostic value of serum neutrophil gelatinase‐associated lipocalin in metastatic and nonmetastatic colorectal cancer
Munoz-Colmenero et al. Plasma tumor M2-pyruvate kinase levels in different cancer types
Jouhi et al. The expression of Toll-like receptors 2, 4, 5, 7 and 9 in Merkel cell carcinoma
Alexander et al. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas
Yan et al. Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients
Stefaniak et al. Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation
Marín-Rubio et al. S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma
Ellinger et al. Evaluation of global histone acetylation levels in bladder cancer patients
Heubner et al. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer
JP2015521728A5 (https=)
Jessica Mok et al. Is C-reactive protein the single most useful predictor of difficult laparoscopic cholecystectomy or its conversion? A pilot study